The ChIP-seq-defined networks of Bcl-3 gene binding support its required role in skeletal muscle atrophy
Jackman, Robert W.
Kandarian, Susan C.
MetadataShow full item record
Citation (published version)Robert W Jackman, Chia-Ling Wu, Susan C Kandarian. 2012. "The ChIP-seq-defined networks of Bcl-3 gene binding support its required role in skeletal muscle atrophy.." PLoS One, Volume 7, Issue 12, pp. e51478 - ?.
NF-kappaB transcriptional activation is required for skeletal muscle disuse atrophy. We are continuing to study how the activation of NF-kB regulates the genes that encode the protein products that cause atrophy. Using ChIP-sequencing we found that Bcl-3, an NF-kB transcriptional activator required for atrophy, binds to the promoters of a number of genes whose collective function describes two major aspects of muscle wasting. By means of bioinformatics analysis of ChIP-sequencing data we found Bcl-3 to be directing transcription networks of proteolysis and energy metabolism. The proteolytic arm of the Bcl-3 networks includes many E3 ligases associated with proteasomal protein degradation, including that of the N-end rule pathway. The metabolic arm appears to be involved in organizing the change from oxidative phosphorylation to glycolysis in atrophying muscle. For one gene, MuRF1, ChIP-sequencing data identified the location of Bcl-3 and p50 binding in the promoter region which directed the creation of deletant and base-substitution mutations of MuRF1 promoter constructs to determine the effect on gene transcription. The results provide the first direct confirmation that the NF-kB binding site is involved in the muscle unloading regulation of MuRF1. Finally, we have combined the ChIP-sequencing results with gene expression microarray data from unloaded muscle to map several direct targets of Bcl-3 that are transcription factors whose own targets describe a set of indirect targets for NF-kB in atrophy. ChIP-sequencing provides the first molecular explanation for the finding that Bcl3 knockout mice are resistant to disuse muscle atrophy. Mapping the transcriptional regulation of muscle atrophy requires an unbiased analysis of the whole genome, which we show is now possible with ChIP-sequencing.
RightsCopyright: © 2012 Jackman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Showing items related by title, author, creator and subject.
Whitesell, Luke; Robbins, Nicole; Huang, David S.; McLellan, Catherine A.; Shekhar-Guturja, Tanvi; LeBlanc, Emmanuelle V.; Nation, Catherine S.; Hui, Raymond; Hutchinson, Ashley; Collins, Cathy; Chatterjee, Sharanya; Trilles, Richard; Xie, Jinglin L.; Krysan, Damian J.; Lindquist, Susan; Porco, John A.; Tatu, Utpal; Brown, Lauren E.; Pizarro, Juan; Cowen, Leah E. (Nature Publishing Group, 2019-01-24)
Jin, Caining; Rajabi, Hasan; Rodrigo, Christina M.; Porco, John A.; Kufe, Donald (2013-04-25)The oncogenic MUC1-C subunit is aberrantly overexpressed in most human breast cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non- malignant MCF-10A cells with ...
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma Schatz, Jonathan H.; Oricchio, Elisa; Wolfe, Andrew L.; Jiang, Man; Linkov, Irina; Maragulia, Jocelyn; Shi, Weiji; Zhang, Zhigang; Rajasekhar, Vinagolu K.; Pagano, Nen C.; Porco, John A.; Teruya-Feldstein, Julie; Rosen, Neal; Zelenetz, Andrew D.; Pelletier, Jerry; Wendel, Hans-Guido (2011-08-29)New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic ...